07/11/2024
From our Chief Medical Officer John K. Scott:
"We are excited to announce the recent approval of . It’s times like these that raise our hopes toward the eventual development of a treatment to end human suffering from such a condition.
As we continue to expand on the current knowledge and disease target mechanisms, we expect to slow the rate of memory decline until there is no further progression. Coupled with earlier screening and detection methods, the ability to help patients in the earliest stages maintain their quality of life, independence, and lessen the caregiver burden so that they also may lead productive lives no longer sounds like impossible science fiction.
National Clinical Research, Inc. has contributed significantly to ’s disease clinical research and we plan to continue conducting quality studies until the above vision has been achieved.
We could not enjoy the rewards of our efforts today without an exceptional team of coordinators, recruiters, raters, managers, greeters, mixers, phlebotomists, and physicians. Thank you for your continued tenacious spirit, integrity and compassion in this work.
We also have to thank the hundreds of patient volunteers who come to our clinic seeking help and willing to take a leap into the unknown world of . They have put their confidence in us to provide opportunities that may benefit not only themselves but the greater community. Our patients are the true trailblazers for which donanemab has proven successful."
; 's
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
